INSIGHTS ON DRUG DEVELOPMENT

• Characterizing mRNA Using Ion-Pairing Reversed-Phase LC/MS

  mRNA poly(A) tail analysis depends on targeted digestion, clean LC/MS conditions, and reliable deconvolution. See how RNase 4 digestion and optimized ion-pairing methods support reproducible results.

• Injection Site Reaction Screening Methodology

  Optimize drug formulations for solubility at physiological pH to reduce injection site reactions, enable high-concentration dosing, and enhance patient comfort and compliance.

• Exosome Production From hMSC Using A Fixed-Bed Bioreactor

  Explore a high-yield, scalable process for hMSC-derived exosome production using fixed-bed bioreactors, with strong performance in purity, recovery, and biological activity.

• Small Molecule Orphan Drugs: Status Quo, Challenges, And Perspectives

  By establishing robust manufacturing processes and scalable production strategies from the outset, developers can help de-risk orphan drug production, improve efficiency, and position their programs for greater long-term success.

• Analyzing Biological Drug Effects In 3D

  10/24/2025

  Explore how 3D tumor microtissues paired with fluorescence-based assays offer scalable, high-sensitivity drug testing to deliver stronger signals and reproducible results compared to monolayer cultures.

• Drug Development Plan Explained: DPP Templates And Examples

  7/27/2026

  Only 6.7% of Phase 1 drugs reach approval. A well-structured Drug Development Plan (DDP) can meaningfully improve your odds — learn exactly how to build one.

• Method Development For Forced Degradation Of GLP-1 Agonist

  3/18/2026

  Gain insight into how a systematic approach reveals impurity behavior, strengthens selectivity, and refines chromatographic conditions to build a reliable degradation method for a GLP‑1 agonist.

• Keeping Future Manufacturing Options Open During Development

  7/24/2026

  Early choices affect manufacturing flexibility, tech transfer, and supply chain resilience. Addressing IP and production needs early helps preserve options for commercialization.

• The Top Tech Transfer Risks At Multi-Site CDMOs

  3/31/2026

  Many tech transfer risks are avoidable with a single campus CDMO. With all manufacturing facilities on one site, drug sponsors can overcome obstacles and maintain speed en route to market.